综述:用于炎症性肠病的抗β7整合素疗法依曲利珠单抗的非临床与临床药理学、药代动力学及药效学
依曲利珠单抗是靶向β7整合素的单克隆抗体,正在炎症性肠病(IBD)中开展III期临床评估。本综述汇总其非临床与临床数据,显示其通过抑制白细胞向肠道迁移及上皮层内滞留的双重机制发挥肠道选择性作用,皮下100 mg或更高每4周一次呈线性药代动力学,该剂量足以使中重度溃疡性结肠炎患者血和肠道组织β7受体完全占据。
要点
- 依曲利珠单抗特异性靶向α4β7和αEβ7整合素的β7亚基,不结合α4β1整合素。
- 其肠道选择性源于独特双重机制:抑制白细胞向肠道黏膜迁移及在肠上皮层内滞留。
- 中重度溃疡性结肠炎患者皮下注射100 mg或更高每4周一次呈线性药代动力学,足以完全占据血和肠道组织β7受体。
核心结论
- 依曲利珠单抗是一种肠道选择性抗β7整合素单克隆抗体,可能对炎症性肠病具有治疗潜力。
研究设计与样本
- 综述已发表及内部未发表的依曲利珠单抗非临床与临床研究数据。
主要发现
- 依曲利珠单抗通过独特双重机制发挥作用,既抑制白细胞向肠道黏膜迁移,又抑制其在肠上皮层内滞留。
- 其肠道选择性源于特异性靶向α4β7和αEβ7整合素的β7亚基,且不结合介导淋巴细胞向包括中枢神经系统在内组织迁移的α4β1整合素。
- 溃疡性结肠炎患者的I/II期研究显示,皮下给予100 mg或更高剂量每4周一次时呈线性药代动力学。
- 该剂量足以使中重度溃疡性结肠炎患者血和肠道组织中的β7受体完全占据。
- II期研究结果提示,肠道αE整合素表达升高的患者对依曲利珠单抗治疗产生临床缓解的可能性可能增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Novel treatments with superior benefit-risk profiles are needed to improve the long-term prognosis of patients with inflammatory bowel disease (IBD). Etrolizumab-a monoclonal antibody that specifically targets β7 integrins-is currently under phase III clinical evaluation in IBD. AIM: This review summarises the available pharmacological and pharmacokinetic/pharmacodynamic data for etrolizumab to provide a comprehensive understanding of its mechanism of action (MOA) and pharmacological effects. METHODS: Published and internal unpublished data from nonclinical and clinical studies with etrolizumab are reviewed. RESULTS: Etrolizumab exerts its effect via a unique dual MOA that inhibits both leucocyte trafficking to the intestinal mucosa and retention within the intestinal epithelial layer. The gut-selectivity of etrolizumab results from its specific targeting of the β7 subunit of α4β7 and αEβ7 integrins. Etrolizumab does not bind to α4β1 integrin, which mediates lymphocyte trafficking to tissues including the central nervous system, a characteristic underlying its favourable safety with regard to progressive multifocal leucoencephalopathy. Phase I/II studies in patients with ulcerative colitis (UC) showed linear pharmacokinetics when etrolizumab was administered subcutaneously at 100 mg or higher once every 4 weeks. This dose was sufficient to enable full β7 receptor occupancy in both blood and intestinal tissues of patients with moderate to severe UC. The phase II study results also suggested that patients with elevated intestinal expression of αE integrin may have an increased likelihood of clinical remission in response to etrolizumab treatment. CONCLUSION: Etrolizumab is a gut-selective, anti-β7 integrin monoclonal antibody that may have therapeutic potential for the treatment of IBD.
引用
- Tang MT, Keir ME, Erickson R, et al. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease. Aliment Pharmacol Ther. 2018. PMID: 29601644. doi:10.1111/apt.14631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。